Stabilyte™ tubes that contain strongly acidic citrate prevent in vitro complex formation between activated protein C and protein C inhibitor

Thrombosis and Haemostasis

Volumn 89, Issue 5, 2003, Pages 947-949

  Strandberg, Karin ^b   Svensson, Anita ^b   Stenflo, Johan ^a  

^a LUND UNIVERSITY   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BENZAMIDINE; CITRIC ACID; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 3; DIAGNOSTIC AGENT; PROTEIN C;

ACCURACY; ACIDITY; ANALYTIC METHOD; ASSAY; BINDING AFFINITY; BLOOD SAMPLING; CLINICAL CHEMISTRY; COMPLEX FORMATION; DISEASE SEVERITY; DOSE RESPONSE; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; LETTER; MEDICAL DECISION MAKING; PH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; TUBE; IMMUNOASSAY; METABOLISM; METHODOLOGY; PROTEIN BINDING; STANDARD;

ANTIBODIES, MONOCLONAL; BLOOD SPECIMEN COLLECTION; CITRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOASSAY; PROTEIN BINDING; PROTEIN C; PROTEIN C INHIBITOR;

EID: 0037954200     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613485     Document Type: Letter

References (9)

1. Powars D, Larsen R, Johnson J, Hulbert T, Sun T, Patch MJ, Francis R, Chan L. Epidemic Meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 1993; 17: 254-61.
2. Faust S, Levin M, Harrison O, Goldin R, Lockhart M, Kondaveeti S, Laszik Z, Esmon C, Heyderman R. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345: 408-16.
3. Bernard G, Vincent J-L, Laterre P-F, LaRosa S, Dhainaut J-F, Lopez-Rodriguez A, Steingrub J, Garber G, Helterbrand J, Ely W, Fisher C. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
4. Gruber A, Griffin JH. Direct detection fo activated protein C in blood from human subjects. Blood 1992; 79: 2340-8.
5. Espana F, Vicente V, Tabernero D, Scharrer I, Griffin JH. Determination of plasma protein C inhibitor and of two activated protein c-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 1990; 59: 593-608.
6. Strandberg K, Kjellberg M, Erb E-M, Persson U, Mosher DF, Villoutreix B, Stenflo J. Activated protein C-protein C inhibitor complex formation: Characterization of a neoepitope provides evidence for extensive insertion of the reactive center loop. Biochemistry 2000; 39: 15713-20.
7. Standberg K, Kjellberg M, Knebel R, Lilja H, Stenflo J. A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: Use of a catcher antibody specific for the complexed/cleaved form of the inhibitor. Thromb Haemost 2001; 86: 607-10.
8. Strandberg K, Astermark J, Björgell O, Becker C, Nilsson PE, Stenflo J. Complexes between activated protein C and protein C inhibitor measured with a new method. Comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis. Thromb Haemost 2001 ; 86: 1400-8.
9. Espana F, Griffin JH. Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISA's. Thromb Res 1989l; 55: 671-82.